Jan 19 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd 002399.SZ :
* Says its controlling Shenzhen-based biotech subsidiary gets approval for new drug Ib/IIa clinical trial in Australia
* The new drug is used for treatment of hyperlipemia
Jan 19 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd 002399.SZ :
* Says its controlling Shenzhen-based biotech subsidiary gets approval for new drug Ib/IIa clinical trial in Australia
* The new drug is used for treatment of hyperlipemia